Dosing Begins in Phase 3 Trial of Fasenra, an Asthma Therapy, to Treat EGPA

Dosing Begins in Phase 3 Trial of Fasenra, an Asthma Therapy, to Treat EGPA

281744

Dosing Begins in Phase 3 Trial of Fasenra, an Asthma Therapy, to Treat EGPA

Patient dosing has begun in a Phase 3 clinical trial investigating the asthma treatment Fasenra (benralizumab) in people with eosinophilic granulomatosis with polyangiitis (EGPA), a subtype of ANCA-associated vasculitis. AstraZeneca, which markets Fasenra, also announced the start of dosing in two other Phase 3 trials: one in people with hypereosinophilic syndrome (NCT04191304) and one in those with eosinophilic esophagitis (NCT04543409). It also plans to initiate a trial in eosinophilic gastritis/eosinophilic gastroenteritis. These are all rare…

You must be logged in to read/download the full post.